Daniel A. de Boer is a Dutch serial entrepreneur and the founding Chief Executive Officer of ProQR Therapeutics since the company’s incorporation in 2012. When Daniel’s newborn son was diagnosed with a genetic rare disease he decided to start ProQR to develop drugs for rare genetic diseases. Today ProQR is a publically traded company (NASDAQ:PRQR), with offices in Leiden the Netherlands and Cambridge, Massachusetts, developing medicine for severe genetic diseases that have no treatment options, including several forms of genetic blindness, a life-threatening blistering disease dystrophic epidermolysis bullosa and lung disease cystic fibrosis. Prior to founding ProQR, Daniel was the founder and CEO of several IT companies, including RNA Systems, PC Basic and Running IT, that he led through several phases of growth. Daniel is also co-founder and advisor to the CEO at Amylon Therapeutics.